NRAS mutations at codons 12 and 61 activate pathways including IL1, JAK/STAT, and NF-κB, promoting an inflammatory tumor microenvironment, enhancing cell proliferation and survival, and contributing to therapy resistance [43]. Here, NRAS is linked to neoplasm.